Our Solution
Modern biologics are becoming increasingly complex in order to increase therapeutic efficacy and safety
Single chain to clone selection
mAb
Bi-specific antibodies
Bispecific
Novel formats & fusions
Multi-domain & fusion
Complex / Toxic / Hard-to-express
Multi-domain & fusion
Current Cell Lines are not ready for tomorrow's complex molecules, leading to the issue with current platforms
Ultimately, this prevents these powerful drugs from reaching patients. This is because conventionally, once a cell line is created, gene expression is fixed, always on, at a set level.
Low developability
Complex structures often misfold, leading to poor yield and unstable cell lines.
Problems during scaling
Processes that work in small scale fail unpredictably in massive bioreactors.
Reduced program value
High COGS and extended timelines reduce the commercial viability of therapeutics.
Prolific introduces a revolutionary new approach, deployed in your existing platform
Precise control over the expression of any gene, driving higher titers, superior on-target quality, and precise process control for even the most complex biologics.
A manufacturing process that works with biology, not against it
Illumination systems
We add light control to any bioreactor, delivering fast, flexible, and scalable biomanufacturing capacity without disruption to existing infrastructure.
Optogenetic Cell Line Development
We enhance any host cell line with a light-inducible expression system, enabling precise, programmable gene expression control for higher titers and superior product quality.
Data‑Driven Process Optimization
We leverage real-time process data and AI models to dynamically adjust light, maximizing yield and product quality at every scale.
Optogenetic control enables new strategies for expressing complex or difficult molecules while maintaining the same CLD timeline
Optogenetic Host Cell Line Set-up (One time)
Vector engineering
We use light-inducible promoters instead of constitutive promoters
Stable pool to clone selection
Dynamically controllable protein expression during the cell culture process
Decouple growth from production
Cells grow to high density before production begins, eliminating the growth-productivity trade-off.
Tune expression in real time
Expression levels are adjusted dynamically during the culture process, not locked in at cell line creation, enabling higher titers
Control product quality
Biological pathways influencing critical quality attributes can be adjusted for the desired product profile.
A step-change in complex biologics manufacturing
Industry-record titer · 15-day fed-batch
The highest reported productivity for a 15 day fed-batch mAb production run — achieved with standard infrastructure.
Partner with usEnables complex therapeutics
Enables complex therapeutics
Provides unprecedented CQA control
Precise, light-driven control over critical quality attributes.
Drop-in compatible
Works with your existing CLD platforms, processes and bioreactors.
Illuminating biomanufacturing, enabling tomorrow's biotherapeutics
“Everybody wants to wake up in the morning with their cells making twice as much protein without changing anything. Prolific actually delivers that step change in performance, while leveraging all your existing infrastructure.”
- Deniz Kent, CEO